June 2021 - Linnaeus

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer

By wpteam|2021-06-16T10:15:45+00:00June 16th, 2021|

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer Studies Will be Conducted at Multiple NCI-Designated Comprehensive Cancer Centers Haddonfield NJ, June 15, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical [...]

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting

By wpteam|2021-06-08T10:31:47+00:00June 8th, 2021|

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting Haddonfield NJ, June 7, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of [...]